The Working Group on Regulatory Matters aims to promote research on and development of innovative medicinal products by removing unnecessary bureaucracy and current obstacles in the regulatory parameters. Among other topics, it deals with the conditions for clinical trials, the legal framework for medicinal products for innovative therapies, and the national, European and international legal provisions for trialling and licensing biopharmaceutical products. In addition, the working group aims to improve collaboration between companies, hospitals and doctors in research on and development of innovative medicines.
|Dr. Edgar Fenzl||FGK Clinical Research GmbH|